A Phase II Study of Neoadjuvant Botensilimab and Balstilimab Immunotherapy for Mismatch Repair Proficient Rectal Adenocarcinoma
Latest Information Update: 20 Mar 2025
At a glance
- Drugs Balstilimab (Primary) ; Botensilimab (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- 03 Mar 2025 New trial record